Bital Savir-Baruch, MD, FACNM, is a Nuclear Medicine physician practicing a wide variety of both diagnostic imaging and therapeutic interventions. She has particular clinical interest in advanced applications of both clinical and research diagnosis and therapeutic agents.
An expert in precision medicine, Dr. Savir-Baruch focuses on the diagnosis and management of prostate, thyroid, and neuroendocrine cancers. Recently, Dr. Savir started a new outpatient theranostics clinic to treat patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) with the use of the newest FDA-approved targeted therapy, Pluvicto* (to reach the clinic regarding Pluvicto therapy, call (520) 694-0111.)
Dr. Savir-Baruch is passionate about research having investigator experience in several clinical trials. Her philosophy of care is to provide patients with exceptional service in Diagnostic Nuclear Medicine Imaging and Radioablation Therapy. She emphasizes collaboration among a team of talented Nuclear Medicine physicians, Nuclear Radiologists and technologists, nurses and referring physicians to achieve the highest quality of care.
Dr. Savir-Baruch received her Doctor of Medicine from Semmelweis University in Budapest, Hungary. After completing her medical degree, she accepted a Nuclear Medicine Research Associate position at Emory University’s Department of Radiology and Imaging Science. Following her general surgery internship, Dr. Savir-Baruch completed a nuclear medicine residency at Emory University. Dr. Savir-Baruch is board-certified in nuclear medicine and nuclear cardiology.
Dr. Savir-Baruch is a Fellow of the American College of Nuclear Medicine and serves as the 2023 Vice President of ACNM. She is the recent recipient of the ACNM President’s Award and the Award for Best Clinical Mentor, 2022.
Additionally, Dr. Savir-Baruch serves as Outreach Committee Co-Chair for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Nuclear Oncology: 1) New techniques to guide invasive procedures. 2) the role of novel radiotracers and imaging devices in the detection and management of neoplastic diseases such as prostate, breast, brain, and GYN cancers. 3) study of different strategies aimed at tumor therapy.